Business Context and Reporting Period
This Form 8-K Current Report was filed by 4D Molecular Therapeutics, Inc. on November 16, 2023. The report addresses corporate governance updates rather than financial performance for a specific fiscal period.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is not a financial statement filing and contains no quantitative financial data.
Material Changes
On November 16, 2023, the Board of Directors amended and restated the Company's bylaws. The material changes include:
- Updates to advance notice procedures for business brought before a meeting.
- Updates to advance notice procedures for nominations of directors.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document focuses solely on the procedural amendment of the bylaws.
Key Facts for Investors
- The Company is an emerging growth company.
- Common Stock trades on The Nasdaq Global Select Market under the symbol FDMT.
- The full text of the Amended and Restated Bylaws is available as Exhibit 3.1 to this filing.
- The report was signed by Uneek Mehra, Chief Financial and Business Officer, on November 22, 2023.